|
|
|
A neutralizing human antibody has previously been shown to protect against HIV in a monkey model. Dennis R. Burton and colleagues report in Nature that the protective effect is not only due to the antibody's neutralizing activity, that is, its ability to block viral entry into target cells, but also to antiviral responses due to the antibody's ability to bind to Fc receptors on effector cells. Antibody-activated effector cells can act against both free virus and against virus-infected cells.
The study implies that prevention of HIV infection may require activity against both free virions and infected cells, and that vaccine efficacy may be crucially dependent on its ability to elicit a combination of antibody and cell-mediated immunity. CONTACT Dennis R. Burton (The Scripps Research Institute, La Jolla, CA, USA) E-mail: burton@scripps.edu John Mascola (NIH, Bethesda, MD, USA) E-mail: jmascola@mail.nih.gov (C) Nature press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|